Short-term Effect of Endostar/Bevacizumab in Combination with Paclitaxel and Platinum for Advanced Lung Adenocarcinoma

Objective To observe the safety and short-term efficacy of endostar/bevacizumab combined with paclitaxel and platinum in the treatment for advanced lung adenocarcinoma. Methods We retrospectively analyzed 128 stage ⅢB and Ⅳ lung adenocarcinoma patients confirmed histologically from January 2010 to June 2013, 48 patients in the chemotherapy alone group, 44 patients in the endostar plus chemotherapy group(endostar group) and 36 patients in the bevacizumab plus chemotherapy group(bevacizumab group). Then we observed the short-term efficacy and safety by Chi-square test and Ridit analysis. Results The objective response rates (ORR) and disease control rates(DCR) of endostar group and bevacizumab group were 31.8%, 59.1% and 36.1%, 80.5% superior to those of chemotherapy alone group(14.5%, 39.5%) (P<0.05). There was no obvious difference in adverse reactions among three groups(P>0.05). Conclusion Targeted drug combined with chemotherapy has good curative effect in the treatment for advanced lung adenocarcinoma and the untoward effect was tolerable. Beacizumab is superior to endostar in controlling the progress of the disease.